This trial is active, not recruiting.

Conditions implant clinical survival, dental implant bone loss
Treatment ice dental implant
Phase phase 4
Sponsor Alpha - Bio Tec Ltd.
Start date January 2015
End date January 2018
Trial size 35 participants
Trial identifier NCT01960361, ICE_001


The current prospective clinical study's aim is to determine ABT's ICE implant survival rate, crestal interproximal bone resorption during 24 months post implant insertion and to assimilate the drilling sequence during the clinical use of ICE implants.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Intervention model single group assignment
Masking open label
Primary purpose treatment
Subjects implanted with ICE implant
ice dental implant
ICE- Implant Classical Esthetic implant

Primary Outcomes

Cumulative Survival Rate
time frame: 24 MONTHS

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: 1. Men and women over the age of 18 years who need implantation of 1-4 implants. 2. Patients who are able to understand the requirements of the study, and are willing and able to comply with its instructions and schedules. 3. Patients who had provided written informed consent to participate in the study prior to any study procedure. 4. Patients in general good health in the opinion of the principal investigator as determined by medical history and oral examination. Exclusion Criteria: 1. Immediate loaded implants. 2. Treatment with anticoagulant drugs (INR under 1.8) or bisphosphonates. 3. Treatment with anticonvulsants drugs. 4. Untreated Periodontal disease and inability of the patient to maintain reasonable oral hygiene according to study requirements. 5. Patients with history of alcohol, narcotics or drug abuse. 6. Patients under steroid therapy. 7. Patients receiving radiotherapy, chemotherapy or any other immunosuppressive treatment or who have been administered radiotherapy in the last 5 years. Patients through at anytime received radiotherapy to the head and neck region will be excluded anyway. 8. Metabolic bone disorders and/or bone augmentation. 9. Uncontrolled bleeding disorders such as: hemophilia, thrombocytopenia, granulocytopenia. 10. Degenerative diseases. 11. Osteoradionecrosis. 12. Renal failure. 13. Organ transplant recipients. 14. HIV positive. 15. Malignant diseases. 16. Diseases that compromise the immune system. 17. Unbalanced diabetes mellitus. (HbA1c above 6.5) 18. Psychotic diseases. 19. Hypersensitivity to one of the components of the implant in general and titanium in particular. 20. Women who are pregnant or lactating. 21. Lack of patient cooperation. 22. Uncontrolled endocrine diseases. 23. Any systemic condition that is unbalanced and therefore precludes surgical procedures. 24. Parafunctional habits.- e.g Bruxism. 25. Temporomandibular joint disease. 26. Various pathologies of the oral mucosa for example: Benign mucous pemphigoid, desquamative ginigivitis, erosive lichen planus ,malignancy of oral cavity, bolus erosive diseases of the oral mucosa.

Additional Information

Official title A Multi-center Study to Evaluate Bone Loss, Survival Rate and Stability of ICE Implant System Over 24 Months, for Patients With Tooth Loss Requiring up to 4 Implants, in Staged Loading Protocol
Trial information was received from ClinicalTrials.gov and was last updated in June 2016.
Information provided to ClinicalTrials.gov by Alpha - Bio Tec Ltd..